Posted by Michael Wonder on 17 Feb 2023
Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs
14 February 2023 - Medicare advisers on Tuesday recommended that the program alter its requirements for drugs, diagnostics, and medical devices that face coverage restrictions to make the process more transparent and better incorporate diversity data.
The niche regulatory tool, called a Coverage with Evidence Development, has gotten outsized attention recently because it has been applied to a new class of Alzheimer’s drugs that target amyloid plaques in the brain.
